Categories: News

Applied Molecular Transport to Present at Canaccord Genuity’s 41st Annual Growth Conference

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during Canaccord Genuity’s 41st Annual Growth Conference on Wednesday, August 11, 2021 at 2:30 p.m. ET.

A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelial (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.

Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com

Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Staff

Recent Posts

Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement

Both the Mast Hill $3,500,000 Note and the FirstFire $277,777 Note were Paid in Full…

6 hours ago

KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading…

6 hours ago

Bausch Health to Announce First-Quarter 2024 Results on May 2

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will…

6 hours ago

PMD Device Solutions Signs Transfer Agreement for Key Assets in Coala-Life Group AB to Accelerate its US Market Entry

STOCKHOLM, SWEDEN / ACCESSWIRE / April 11, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) ("PMDS") today…

6 hours ago

Sober Safe Spot is Coming to Thunder Over Louisville

For the first time, Sober Safe Spot will bring their safe zone to Kentucky's "Thunder…

6 hours ago